Julian G.
- Country
- Germany
- Department
- Campus Lübeck, Neurologie
Research Overview
- Safety and Tolerability Evaluation of QRL-201 in Patients with Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
- Multiple Ascending Dose Evaluation of LY4256984 in Patients with Sporadic Amyotrophic Lateral Sclerosis
- A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Usnoflast in Adults with Amyotrophic Lateral Sclerosis
Data & Insights
Has run more than one trial at 74 of 175 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in treating and researching amyotrophic lateral sclerosis (ALS), focusing on innovative therapeutic approaches for managing disease progression and improving patient outcomes.
- Disease progression management
- Ventilation-free survival assessment
- Functional capacity preservation
The research encompasses evaluation of novel compounds targeting ALS pathophysiology.
Neuromuscular Disorders
The investigator conducts research in generalized myasthenia gravis (gMG), with particular emphasis on developing treatments that improve patients' daily living activities and overall function.
- Activities of daily living assessment
- Antibody-mediated therapy evaluation
- Seropositive gMG management
Their work includes assessment of targeted therapeutic interventions for neuromuscular junction disorders.
Clinical Development
The investigator focuses on evaluating novel therapeutic compounds through systematic clinical assessment of safety, tolerability, and efficacy parameters.
- Safety and tolerability studies
- Biomarker analysis
- Pharmacokinetic evaluation
Their expertise includes conducting controlled trials for emerging neurological treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.